In developing immunotherapies, processes and biomarkers are made more complex by the highly heterogenous T cells that form the basis for the therapeutic product or drive the anti-tumor response in various checkpoint and antibody-based immunotherapies.

IsoPlexis provides actionable potency, safety, and patient-difference metrics by detecting highly potent single-cell functional subsets.

Download this eBook to learn how these technological advancements are drastically accelerating the development of novel immunotherapies.